2r3f

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="2r3f" size="350" color="white" frame="true" align="right" spinBox="true" caption="2r3f, resolution 1.50&Aring;" /> '''Crystal Structure of...)
Line 4: Line 4:
==Overview==
==Overview==
-
CDK2 inhibitors containing the related bicyclic heterocycles, pyrazolopyrimidines and imidazopyrazines were discovered through, high-throughput screening. Crystal structures of inhibitors with these, bicyclic cores and two more related ones show that all but one have a, common binding mode featuring two hydrogen bonds (H-bonds) to the backbone, of the kinase hinge region. Even though ab initio computations indicated, that the imidazopyrazine core would bind more tightly to the hinge, pyrazolopyrimidines gain an advantage in potency through participation of, N4 in an H-bond network involving two catalytic residues and bridging, water molecules. Further insight into inhibitor/CDK2 interactions was, gained from analysis of additional crystal structures. Significant gains, in potency were obtained by optimizing the fit of hydrophobic substituents, to the gatekeeper region of the ATP binding site. The most potent, inhibitors have good selectivity. (c) 2007 Wiley Periodicals, Inc., Biopolymers, 2007.
+
CDK2 inhibitors containing the related bicyclic heterocycles pyrazolopyrimidines and imidazopyrazines were discovered through high-throughput screening. Crystal structures of inhibitors with these bicyclic cores and two more related ones show that all but one have a common binding mode featuring two hydrogen bonds (H-bonds) to the backbone of the kinase hinge region. Even though ab initio computations indicated that the imidazopyrazine core would bind more tightly to the hinge, pyrazolopyrimidines gain an advantage in potency through participation of N4 in an H-bond network involving two catalytic residues and bridging water molecules. Further insight into inhibitor/CDK2 interactions was gained from analysis of additional crystal structures. Significant gains in potency were obtained by optimizing the fit of hydrophobic substituents to the gatekeeper region of the ATP binding site. The most potent inhibitors have good selectivity. (c) 2007 Wiley Periodicals, Inc. Biopolymers, 2007.
==About this Structure==
==About this Structure==
Line 14: Line 14:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Duca, J.S.]]
+
[[Category: Duca, J S.]]
-
[[Category: Fischmann, T.O.]]
+
[[Category: Fischmann, T O.]]
-
[[Category: Hruza, A.W.]]
+
[[Category: Hruza, A W.]]
-
[[Category: Madison, V.M.]]
+
[[Category: Madison, V M.]]
[[Category: ACE]]
[[Category: ACE]]
[[Category: SC8]]
[[Category: SC8]]
Line 33: Line 33:
[[Category: transferase]]
[[Category: transferase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 10:53:49 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:44:18 2008''

Revision as of 16:44, 21 February 2008


2r3f, resolution 1.50Å

Drag the structure with the mouse to rotate

Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor

Overview

CDK2 inhibitors containing the related bicyclic heterocycles pyrazolopyrimidines and imidazopyrazines were discovered through high-throughput screening. Crystal structures of inhibitors with these bicyclic cores and two more related ones show that all but one have a common binding mode featuring two hydrogen bonds (H-bonds) to the backbone of the kinase hinge region. Even though ab initio computations indicated that the imidazopyrazine core would bind more tightly to the hinge, pyrazolopyrimidines gain an advantage in potency through participation of N4 in an H-bond network involving two catalytic residues and bridging water molecules. Further insight into inhibitor/CDK2 interactions was gained from analysis of additional crystal structures. Significant gains in potency were obtained by optimizing the fit of hydrophobic substituents to the gatekeeper region of the ATP binding site. The most potent inhibitors have good selectivity. (c) 2007 Wiley Periodicals, Inc. Biopolymers, 2007.

About this Structure

2R3F is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Cyclin-dependent kinase, with EC number 2.7.11.22 Full crystallographic information is available from OCA.

Reference

Structure-guided discovery of cyclin-dependent kinase inhibitors., Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V, Biopolymers. 2007 Oct 15;. PMID:17937404

Page seeded by OCA on Thu Feb 21 18:44:18 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools